Navigation Links
CytoSorbents to Present at the 2014 Rodman & Renshaw Annual Global Investment Conference
Date:9/3/2014

MONMOUTH JUNCTION, N.J., Sept. 3, 2014 /PRNewswire/ -- CytoSorbents Corporation (OTCQB: CTSO) announced that Chief Executive Officer, Dr. Phillip Chan, MD, PhD, will present at the Rodman & Renshaw Annual Global Investment Conference (sponsored by H.C. Wainwright & Co) taking place on September 8-10th in New York City.   CytoSorbents is a critical care immunotherapy company commercializing its CytoSorb® cytokine adsorber to treat patients with life-threatening inflammatory conditions in the intensive care unit in nineteen countries worldwide.

Conference Presentation Details:
Where:  New York Palace Hotel, 455 Madison Avenue, New York, NY 10022
When:  Tuesday, September 9th at 2:05 PM
Room:   Kennedy II Salon (4th Floor)
Webcast:  http://wsw.com/webcast/rrshq24/ctso
Conference Website:  Rodman and Renshaw 16th Annual Global Investment Conference

About CytoSorbents Corporation
CytoSorbents Corporation is a critical care focused immunotherapy company using blood purification to modulate inflammation -- with the goal of preventing or treating multiple organ failure in life-threatening illnesses. Organ failure is the cause of nearly half of all deaths in the intensive care unit, with little to improve clinical outcome. CytoSorb®, the Company's flagship product, is approved in the European Union as a safe and effective extracorporeal cytokine adsorber, designed to reduce the "cytokine storm" that could otherwise cause massive inflammation, organ failure and death in common critical illnesses such as sepsis, burn injury, trauma, lung injury, and pancreatitis. These are conditions where the risk of death is extremely high, yet no effective treatments exist. CytoSorb® is also being used during and after cardiac surgery to try to remove inflammatory mediators, such as cytokines and free hemoglobin, which can lead to post-operative complications, including multiple organ failure.

CytoSorbents' purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. CytoSorbents has numerous products under development based upon this unique blood purification technology, protected by 32 issued US patents and multiple applications pending, including HemoDefend™, ContrastSorb, DrugSorb, and others. Additional information is available for download on the Company's website: http://www.cytosorbents.com/

Forward-Looking Statements
This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release are not promises or guarantees and are subject to risks and uncertainties that could cause our actual results to differ materially from those anticipated. These statements are based on management's current expectations and assumptions and are naturally subject to uncertainty and changes in circumstances. We caution you not to place undue reliance upon any such forward-looking statements. Actual results may differ materially from those expressed or implied by the statements herein. Risk factors are detailed in the Company's Form 10-K filed with the SEC on March 31, 2014, which is available at http://www.sec.gov.

Logo - http://photos.prnewswire.com/prnh/20140408/MM00899LOGO


'/>"/>
SOURCE CytoSorbents Corporation
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. CytoSorbents Records Another Solid Quarter of Growth in Q2 2014
2. CytoSorbents Expands Distribution to Taiwan with Hemoscien Corporation
3. CytoSorbents Receives Approximately $400,000 in Non-Dilutive Capital from the Sale of Net Operating Loss Carryovers
4. Inovio to Present at Upcoming Investor Conferences
5. Isis Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Conference
6. RXi Pharmaceuticals to Present at the Rodman & Renshaw 16th Annual Global Investment Conference
7. Relmada Therapeutics to Present at the 16th Annual Rodman & Renshaw Global Investment Conference in New York City September 8-10th, 2014
8. Avanir Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Conference
9. Abaxis, Inc. to Present at the Morgan Stanley Global Healthcare Conference
10. Volcano Corporation Presentation At Morgan Stanley Conference To Be Webcast
11. Hologic to Present at the Morgan Stanley Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... Inc. (NASDAQ: MSON ), an international surgical ... therapeutic ultrasonic products for spine surgery, skull-based surgery, ... other surgical applications, today announced financial results for ... fiscal year 2016 ended December 31, 2015. ... Highlights for the second quarter and first half ...
(Date:2/9/2016)... 2016 QGEN ; ... Abschluss eines Kooperationsvertrags mit 10x Genomics für ... den Bereichen Next-Generation-Sequencing (NGS), Single-Cell-Biology und Bioinformatik ... Prime Standard: QIA) gab heute den Abschluss ... Entwicklung und Förderung umfassender Lösungen in den ...
(Date:2/9/2016)... --  AllCare Plus Pharmacy announced today that it ... ® for Home Care Accreditation by ... Seal of Approval ® is a symbol of ... and effective care.  --> ... on-site survey in January 2016. The survey reflected compliance ...
Breaking Medicine Technology:
(Date:2/9/2016)... ... February 09, 2016 , ... Two renowned photographers, Robert Caplin (New ... adventure on the island, June 14-19, 2016, hosted by Four Seasons Resort Maui at ... After a successful debut in 2015, the Maui Photo Expedition workshop will ...
(Date:2/9/2016)... Atlanta, G.A. (PRWEB) , ... February 09, 2016 ... ... tile and grout cleaning and sealing company , is proud to announce that ... for their superior levels of customer service. The hard surface restoration franchises received ...
(Date:2/9/2016)... St. Petersburg, FL (PRWEB) , ... February 09, 2016 , ... Shark Finds ... of a new DRTV campaign with GRIP-DRY. , GRIP-DRY is a newly patented product that ... carts. Golfers who play in the wet and early morning dew or right after a ...
(Date:2/8/2016)... ... February 08, 2016 , ... CURE Media Group ... officially launched the Multiple Myeloma Heroes Awards event , which will annually honor ... lives of patients with MM. The MM Heroes Awards nomination process is ...
(Date:2/8/2016)... ... 08, 2016 , ... Brenntag Specialties, Inc.(BSI) , is ... & Beverage and Dietary Supplement market segments across the western ... geographies east of the Rocky Mountains since 2012. Consistent performance in business ...
Breaking Medicine News(10 mins):